Preclinically, the inhibition of HIF1a by EZN‐2968 enhanced the therapeutic efficacy of PD‐1 blockade in the treatment of both melanoma and TNBC by reducing the infiltration of ALCAMhigh macrophages and exhausted CD8+ T cells and promoting anti‐tumor immunity. Here, PDCD1 is linked to neoplasm.